Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSierra Health and Life Elevidys Coverage Update | …
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0126F

    Elevidys (delandistrogene moxeparvovec-rokl) — Medical Benefit Drug Policy (coverage criteria)

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0126F alerts

    Get alerted when Policy 2026D0126F changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage criteria and limits for Elevidys gene therapy for treatment of Duchenne muscular dystrophy (DMD) under UnitedHealthcare Commercial/Community Plan benefits; affects prescribers, infusion providers, and prior authorization reviewers.

    Policy Summary
    Payersierra health and life
    PolicyElevidys (delandistrogene moxeparvovec-rokl) — Medical Benefit Drug Policy
    Policy CodePolicy 2026D0126F
    Change TypeCoverage criteria revised (admission restriction added)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionDo not request a planned inpatient admission solely for the purpose of administering Elevidys; prior authorization is required and limited to one lifetime treatment.
    SourceLink
    POLICY UPDATE CHANGES

    Revised coverage criteria; added criterion requiring the provider does not request a planned inpatient admission for the sole purpose of administering Elevidys.

    Archived previous policy version 2025D0126E.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    one lifetimeauthorized treatments per member
    ages 4-5age range covered
    J1413HCPCS code
    G71.01Diagnosis code
    no planned inpatient admissionadministrative restriction
    1previous version archived

    Coverage Criteria for Elevidys

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Primary coverage criteria: Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a pediatric neuromuscular specialist with expertise in the diagnosis of DMD; submission of medical records confirming a DMD gene mutation that is not a deletion in exon 8 or exon 9; patient is aged 4 or 5 years; patient is ambulatory without an assistive device; patient does not have preexisting hepatic impairment, acute liver disease, chronic hepatic condition, or elevated GGT; prescriber attests to weekly liver function monitoring (clinical exam, GGT, total bilirubin) for the first 3 months and thereafter per FDA labeling; patient does not have LVEF < 40% and prescriber attests to weekly troponin-I monitoring for the first month and thereafter per PI; anti-AAVrh74 total binding antibody titer is < 1:400; patient will receive a corticosteroid regimen per FDA approved Elevidys labeling; Elevidys is prescribed by, or in consultation with, a pediatric neuromuscular specialist with DMD treatment expertise; patient will not receive exon-skipping therapies concomitantly or following Elevidys; patient has not previously received gene therapy for DMD; provider does not request a planned inpatient admission for the sole purpose of administering Elevidys; dosing is in accordance with FDA approved labeling; authorization limited to one treatment per lifetime and for no longer than 45 days from approval or until 6 years of age, whichever is first.multiple clinical and laboratory thresholds described

    All conditions must be satisfied for approval

    Revised coverage criterion (admission restriction) — added requirement about inpatient admissions

    Policy history notes a revision to coverage criteria including an added requirement about inpatient admissions.

    Admission criterion: Provider must not request a planned inpatient admission for the sole purpose of administering Elevidys.

    Added in 01/01/2026 revision; archived previous policy version 2025D0126E.

    Elevidys (delandistrogene moxeparvovec-rokl) is not considered medically necessary for certain indications where evidence is insufficient. Specifically, Elevidys is unproven and not medically necessary for: Becker muscular dystrophy (BMD); for Duchenne muscular dystrophy (DMD) in ambulatory patients who are younger than 4 years or 6 years or older; and for DMD patients of any age who are non-ambulatory.

    The policy rationale notes limited trial evidence outside the narrow ambulatory 4–5 year population: neither the EMBARK Phase III trial nor Study 102 (Phase II) demonstrated consistent, statistically significant functional benefit across broader age groups, and only the 4–5 year subgroup showed improvement in NSAA total score at Week 48 in Study 102. Use outside the defined covered population is therefore considered unproven/not medically necessary.

    The policy history was updated effective 01/01/2026 to revise the coverage criteria. The revision adds a requirement that the provider must not request a planned inpatient admission solely for the purpose of administering Elevidys. This admission restriction is now an explicit element of the coverage rationale and may affect approval decisions.

    Coverage is limited to the ambulatory pediatric population in whom benefit has been demonstrated. Use of Elevidys in populations outside the covered ambulatory 4–5 year age group is considered unproven. Likewise, administration to any non-ambulatory patients or to patients with Becker muscular dystrophy (BMD) is regarded as unproven and not medically necessary due to insufficient evidence of improved clinical outcomes.

    Operationally, the revised admission-for-administration condition means that requests which include a planned inpatient admission solely for the purpose of giving Elevidys may be denied under the updated criteria. The 01/01/2026 revision explicitly states the provider must not request such an admission when seeking coverage.

    Initial Therapy Coverage Requirements

    Initial therapy coverage — Initial coverage requires meeting all of the following clinical and administrative requirements

    Initial coverage requires meeting all of the following clinical and administrative requirements.

    Elevidys initial therapy nodes: Diagnosis of Duchenne muscular dystrophy confirmed by or in consultation with a pediatric neuromuscular specialist; documentation of a DMD gene mutation that is not a deletion in exon 8 or exon 9; patient aged 4 or 5 years; ambulatory without an assistive device; no preexisting hepatic impairment/acute liver disease/chronic hepatic condition or elevated GGT with prescriber attestation to weekly liver function monitoring for first 3 months and thereafter per FDA labeling; LVEF ≥ 40% with prescriber attestation to weekly troponin-I monitoring for first month and thereafter per PI; anti-AAVrh74 total binding antibody titer < 1:400; patient will receive corticosteroid regimen per FDA labeling; Elevidys prescribed by or in consultation with a pediatric neuromuscular specialist experienced in DMD treatment; patient will not receive exon-skipping therapies concomitantly or following Elevidys; patient has not previously received gene therapy for DMD; provider does not request planned inpatient admission solely for administration of Elevidys; dosing per FDA approved labeling; prior authorization required and authorization will be issued for no more than one treatment per lifetime and for no longer than 45 days from approval or until 6 years of age, whichever is first.see individual laboratory and age thresholds above

    All listed clinical and administrative requirements must be met for initial coverage approval; associated HCPCS code J1413 links authorization to the treatment.

    Provider Actions, Documentation & Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Authorization will be issued for no more than one Elevidys treatment per lifetime and for no longer than 45 days from approval or until the member reaches 6 years of age, whichever occurs first. Providers must follow UnitedHealthcare Medical Benefit Drug Policy procedures and obtain prior approval before administration.

    • Limit: one treatment per lifetime
    • Authorization duration: <=45 days from approval or until age 6, whichever first
    Note

    Member-specific benefit & mandate check

    Before submitting a request, check the member-specific benefit plan document and any applicable federal or state mandates; the member-specific benefit plan governs in the event of a conflict. This policy is intended to assist interpretation of UnitedHealthcare standard benefit plans but does not replace the member-specific plan or mandates.

    • Verify member-specific benefits and applicable mandates

    Applicable Codes

    Applicable HCPCS CodesHCPCS
    J1413Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose.
    Applicable Diagnosis CodesICD-10
    G71.01Duchenne or Becker muscular dystrophy

    Site of Care Restrictions

    Billing Rule

    Avoid planned inpatient admission for infusion‑center administration

    Planned inpatient admission for the sole purpose of Elevidys administration should not be requested for infusion‑center care; this is an administrative exclusion in the coverage criteria.

    • Do not request planned inpatient admission solely to administer Elevidys
    Billing Rule

    Planned inpatient admission solely for administration is not allowed

    Requests that include planned inpatient admission solely to administer Elevidys are not allowed under the revised coverage criteria for hospital outpatient administration; do not submit inpatient admission requests for this sole purpose.

    • Revised coverage criteria disallow planned inpatient admission solely for administration

    Step Therapy / Concomitant Therapy

    StepRequirement / Restriction
    1Patient must not receive exon‑skipping therapies for DMD (e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), Vyondys 53 (golodirsen)) concomitantly or following Elevidys treatment.

    Quantity Limits

    Elevidys — quantity limit 1
    Quantity limit1 treatment per lifetime
    Percourse / treatment
    Authorization durationNo longer than 45 days from approval or until 6 years of age, whichever is first

    Definitions

    Elevidys (delandistrogene moxeparvovec-rokl) — recombinant AAV-based gene therapy delivering micro-dystrophin
    DrugElevidys (delandistrogene moxeparvovec-rokl)
    DescriptionRecombinant AAV-based gene therapy delivering micro-dystrophin protein (138 kDa) to muscle cells
    Intended effectDelivery of micro-dystrophin transgene to produce shortened functional dystrophin-like protein
    delandistrogene moxeparvovec / SRP-9001 — systemic rAAV-based micro-dystrophin gene delivery for DMD
    Agentdelandistrogene moxeparvovec (SRP-9001)
    ModalitySystemic rAAVrh74.MHCK7 micro-dystrophin gene delivery

    Background

    Duchenne muscular dystrophy (DMD) is a progressive X‑linked neuromuscular disorder caused by mutations in the dystrophin gene, typically presenting in early childhood with progressive muscle weakness that leads to loss of ambulation and life‑threatening cardiopulmonary complications. Elevidys is a recombinant AAV‑based gene therapy that delivers a micro‑dystrophin transgene systemically to skeletal muscle with the goal of producing a shortened functional dystrophin‑like protein.

    Clinical trial evidence has focused on ambulatory pediatric populations; the most robust signal of functional benefit to date has been observed in younger ambulatory children (notably ages 4–5 in Study 102), while data in older or non‑ambulatory patients and in Becker muscular dystrophy are limited or absent. Providers should consider the natural history of DMD and the trial population when evaluating candidates for Elevidys.

    Revision History

    2026-01-01coverage_criteria_revisionLatest

    Revised coverage criteria to add a requirement that the provider must not request a planned inpatient admission solely for the purpose of administering Elevidys.

    2026-01-01archival

    Archived previous policy version 2025D0126E.

    Previous policy versions are retained in the policy history for reference. The 01/01/2026 entry documents the revision that added the inpatient admission restriction and notes that the prior version (2025D0126E) was archived; this is a non‑material archival reference for record keeping.

    Recent clinical literature and trial reports cited in this policy include publications from 2020 through 2023 describing systemic delivery of micro‑dystrophin gene therapies and follow‑up results. Examples include the 2020 JAMA Neurology report of systemic rAAVrh74.MHCK7.micro‑dystrophin delivery and 2023 publications reporting expression and motor function outcomes up to 1–2 years post‑treatment. These references informed the assessment of benefit and the limits of evidence for specific age and functional subgroups.

    Policy Summary
    Payersierra health and life
    PolicyElevidys (delandistrogene moxeparvovec-rokl) — Medical Benefit Drug Policy
    Policy CodePolicy 2026D0126F
    Change TypeCoverage criteria revised (admission restriction added)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionDo not request a planned inpatient admission solely for the purpose of administering Elevidys; prior authorization is required and limited to one lifetime treatment.
    SourceLink
    On This Page
    Coverage Criteria for ElevidysInitial Therapy Coverage RequirementsProvider Actions, Documentation & Denial RisksApplicable CodesSite of Care RestrictionsStep Therapy / Concomitant TherapyQuantity LimitsDefinitionsBackgroundRevision History
  1. In case of conflict, the member-specific benefit plan governs
  2. Documentation Required

    Required Clinical Documentation

    Submit complete medical records to support the request. Required documentation includes confirmation of Duchenne muscular dystrophy diagnosis and genetic testing details, ambulatory status, specialist consultation, baseline laboratory and cardiac assessments, and treatment history.

    • Clinical documentation confirming DMD diagnosis by or in consultation with a pediatric neuromuscular specialist
    • Medical records confirming a DMD gene mutation and that the mutation is not a deletion in exon 8 or exon 9
    • Documentation confirming patient age is 4 or 5 years
    • Records confirming the patient is ambulatory without an assistive device
    • Baseline and planned monitoring documentation: hepatic function (GGT and total bilirubin) and troponin-I monitoring plans as attested by prescriber
    • Documentation that anti-AAVrh74 total binding antibody titer is < 1:400
    • Attestation that a corticosteroid regimen will be given per FDA labeling
    • Documentation that the patient has not previously received gene therapy for DMD
    Denial Risk

    Planned inpatient admission — provider action

    Do not request a planned inpatient admission solely for the purpose of administering Elevidys. Requests for planned inpatient admission for the sole purpose of Elevidys administration may trigger denial.

    • Planned inpatient admission solely for Elevidys administration may be denied
    Denial Risk

    Concomitant therapy restriction

    Patient must not receive exon-skipping therapies for DMD (for example: Amondys, Exondys 51, Viltepso, Vyondys 53) concomitantly with or following Elevidys treatment.

    • Concomitant or subsequent exon-skipping therapies for DMD are prohibited
    Step Therapy

    Step therapy

    No step therapy requirements are specified in this policy.

    Clinical context
    Investigational/clinical trial evidence cited for expression of SRP-9001 dystrophin and motor function stabilization up to 2 years post-treatment